{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05117489",
            "orgStudyIdInfo": {
                "id": "CORT118335-861"
            },
            "organization": {
                "fullName": "Corcept Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)",
            "officialTitle": "A Phase 1b, Open-Label Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Adult Patients With Presumed Nonalcoholic Steatohepatitis (NASH)",
            "therapeuticArea": [
                "Gastroenterology"
            ],
            "study": "a-study-evaluating-the-safety-efficacy-and-pharmacokinetics-of-miricorilant-in-patients-with-presumed-nonalcoholic-steatohepatitis-nash"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-11-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-10-12",
            "studyFirstSubmitQcDate": "2021-11-02",
            "studyFirstPostDateStruct": {
                "date": "2021-11-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-09-28",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-02",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Corcept Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)",
            "detailedDescription": "This phase 1b, Open-Label Study will assess the safety, efficacy and pharmacokinetics (PK) of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH).\n\nPatients who meet the criteria for the study CORT-118335-861 will be enrolled on Day 1 into 1 of 11 cohorts and receive:\n\n* Cohort 1 - a daily dose of 150 mg of miricorilant over 24 weeks.\n* Cohort 2 - a daily dose of 150 mg of miricorilant over 12 weeks.\n* Cohort 3 - a daily dose of 100 mg of miricorilant over 2 weeks, followed by 10 weeks of dosing at 100 mg miricorilant every Monday, Wednesday and Friday.\n* Cohort 4 - a daily dose of 100 mg of miricorilant over 2 weeks, followed by 10 weeks of dosing at 100 mg miricorilant every Monday and Friday.\n* Cohort 5 - a thrice weekly dose of 100 mg of miricorilant over 12 weeks every Monday, Wednesday, and Friday.\n* Cohort 6 - a twice weekly dose of 100 mg of miricorilant over 12 weeks every Monday and Friday.\n* Cohort 7 - a daily dose of 50 mg of miricorilant over 12 weeks.\n* Cohort 8 - a daily dose of 100 mg of miricorilant over 12 weeks.\n* Cohort 9 - a daily dose of 30 mg of miricorilant over 12 weeks.\n* Cohort 10 - a once weekly dose of 200 mg of miricorilant over 12 weeks.\n* Cohort 11 - a twice weekly dose of 150 mg miricorilant over 12 weeks."
        },
        "conditionsModule": {
            "conditions": [
                "Nonalcoholic Steatohepatitis (NASH)"
            ],
            "keywords": [
                "Nonalcoholic Steatohepatitis",
                "NASH",
                "Nonalcoholic Fatty Liver Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 70,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1 - 150 mg of miricorilant for 24 weeks",
                    "type": "EXPERIMENTAL",
                    "description": "Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg once daily, for 24 weeks.",
                    "interventionNames": [
                        "Drug: Miricorilant 150 mg"
                    ]
                },
                {
                    "label": "Cohort 2 - 150 mg of miricorilant for 12 weeks",
                    "type": "EXPERIMENTAL",
                    "description": "Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg once daily, for 12 weeks.",
                    "interventionNames": [
                        "Drug: Miricorilant 150 mg"
                    ]
                },
                {
                    "label": "Cohort 3 - 100 mg daily miricorilant for 2 weeks, followed by 100 mg every MWF for 10 weeks",
                    "type": "EXPERIMENTAL",
                    "description": "Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily for 2 weeks, followed by 100 mg of miricorilant every Monday, Wednesday and Friday for 10 weeks.",
                    "interventionNames": [
                        "Drug: Miricorilant 100 mg"
                    ]
                },
                {
                    "label": "Cohort 4 - 100 mg daily miricorilant for 2 weeks, followed by 100 mg every MF for 10 weeks",
                    "type": "EXPERIMENTAL",
                    "description": "Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily, for 2 weeks, followed by 100 mg of miricorilant every Monday and Friday for 10 weeks.",
                    "interventionNames": [
                        "Drug: Miricorilant 100 mg"
                    ]
                },
                {
                    "label": "Cohort 5 - 100 mg of miricorilant every MWF for 12 weeks",
                    "type": "EXPERIMENTAL",
                    "description": "Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant of 100 mg every Monday, Wednesday and Friday for 12 weeks.",
                    "interventionNames": [
                        "Drug: Miricorilant 100 mg"
                    ]
                },
                {
                    "label": "Cohort 6 - 100 mg of miricorilant every MF for 12 weeks",
                    "type": "EXPERIMENTAL",
                    "description": "Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant of 100 mg every Monday and Friday for 12 weeks.",
                    "interventionNames": [
                        "Drug: Miricorilant 100 mg"
                    ]
                },
                {
                    "label": "Cohort 7 - 50 mg of miricorilant daily for 12 weeks",
                    "type": "EXPERIMENTAL",
                    "description": "Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 50 mg once daily, for 12 weeks.",
                    "interventionNames": [
                        "Drug: Miricorilant 50 mg"
                    ]
                },
                {
                    "label": "Cohort 8 - 100 mg of miricorilant daily for 12 weeks",
                    "type": "EXPERIMENTAL",
                    "description": "Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 100 mg once daily, for 12 weeks.",
                    "interventionNames": [
                        "Drug: Miricorilant 50 mg"
                    ]
                },
                {
                    "label": "Cohort 9 - 30 mg of miricorilant daily for 12 weeks",
                    "type": "EXPERIMENTAL",
                    "description": "Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 30 mg once daily, for 12 weeks.",
                    "interventionNames": [
                        "Drug: Miricorilant 10 mg"
                    ]
                },
                {
                    "label": "Cohort 10 - 200 mg of miricorilant once a week for 12 weeks",
                    "type": "EXPERIMENTAL",
                    "description": "Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 200 mg once weekly, for 12 weeks.",
                    "interventionNames": [
                        "Drug: Miricorilant 50 mg"
                    ]
                },
                {
                    "label": "Cohort 11 - 150 mg of miricorilant twice weekly for 12 weeks",
                    "type": "EXPERIMENTAL",
                    "description": "Patients who meet the entry criteria for study CORT-118335-861 will be enrolled to receive miricorilant as a steady dose of 150 mg twice weekly for 12 weeks.",
                    "interventionNames": [
                        "Drug: Miricorilant 50 mg"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Miricorilant 150 mg",
                    "description": "Miricorilant 150 mg for oral dosing",
                    "armGroupLabels": [
                        "Cohort 1 - 150 mg of miricorilant for 24 weeks",
                        "Cohort 2 - 150 mg of miricorilant for 12 weeks"
                    ],
                    "otherNames": [
                        "CORT118335"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Miricorilant 100 mg",
                    "description": "Miricorilant 100 mg for oral dosing",
                    "armGroupLabels": [
                        "Cohort 3 - 100 mg daily miricorilant for 2 weeks, followed by 100 mg every MWF for 10 weeks",
                        "Cohort 4 - 100 mg daily miricorilant for 2 weeks, followed by 100 mg every MF for 10 weeks",
                        "Cohort 5 - 100 mg of miricorilant every MWF for 12 weeks",
                        "Cohort 6 - 100 mg of miricorilant every MF for 12 weeks"
                    ],
                    "otherNames": [
                        "CORT118335"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Miricorilant 50 mg",
                    "description": "Miricorilant 50 mg for oral dosing",
                    "armGroupLabels": [
                        "Cohort 10 - 200 mg of miricorilant once a week for 12 weeks",
                        "Cohort 11 - 150 mg of miricorilant twice weekly for 12 weeks",
                        "Cohort 7 - 50 mg of miricorilant daily for 12 weeks",
                        "Cohort 8 - 100 mg of miricorilant daily for 12 weeks"
                    ],
                    "otherNames": [
                        "CORT118335"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Miricorilant 10 mg",
                    "description": "Miricorilant 10 mg for oral dosing.",
                    "armGroupLabels": [
                        "Cohort 9 - 30 mg of miricorilant daily for 12 weeks"
                    ],
                    "otherNames": [
                        "CORT118335"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Relative change from Baseline in liver-fat content assessed by MRI-PDFF compared to Baseline.",
                    "timeFrame": "Baseline Day 1 up to Week 24"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change from Baseline in aspartate aminotransferase (AST).",
                    "timeFrame": "Baseline Day 1 up to Week 24"
                },
                {
                    "measure": "Change from Baseline in alanine aminotransferase (ALT).",
                    "timeFrame": "Baseline Day 1 up to Week 24"
                },
                {
                    "measure": "Change from Baseline in gamma-glutamyl transferase (GGT).",
                    "timeFrame": "Baseline Day 1 up to Week 24"
                },
                {
                    "measure": "Change from baseline in enhanced liver fibrosis score (ELF).",
                    "description": "ELF numerical values are calculated from serum measurements of hyaluronic acid (HA), tissue inhibitor of metalloproteinases-1 (TIMP-1), and type III procollagen (PIIINP) using the formula: ELF score = 2.494 + 0.846 In \\[HA\\] + 0.735 In \\[PIIINP\\] + 0.391 In \\[TIMP-1\\], and range on a continuous scale. Liver fibrosis is unlikely with scores \\<6.7 and increasingly likely with higher scores.",
                    "timeFrame": "Baseline Day 1 up to Week 24"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nHave a diagnosis of NASH based on a biopsy obtained within the last year OR Have a diagnosis of presumed NASH based on blood tests and scans\n\nExclusion Criteria:\n\n* Have participated in another clinical trial within the last year and received active treatment for NASH\n* Have participated in another clinical trial for any other indication within the last 3 months\n* Are pregnant or lactating women\n* Have a BMI \\<18 kg/m2\n* Have had liver transplantation or plan to have liver transplantation during the study\n* Have type 1 diabetes or poorly controlled type 2 diabetes.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trial Lead",
                    "role": "CONTACT",
                    "phone": "650-327-3270",
                    "email": "Study861ctgov@corcept.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Kavita Juneja, MD",
                    "affiliation": "Corcept Therapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Site 207",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Chandler",
                    "state": "Arizona",
                    "zip": "85224",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.30616,
                        "lon": -111.84125
                    }
                },
                {
                    "facility": "Site 209",
                    "status": "RECRUITING",
                    "city": "Tucson",
                    "state": "Arizona",
                    "zip": "85712",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.22174,
                        "lon": -110.92648
                    }
                },
                {
                    "facility": "Site 214",
                    "status": "RECRUITING",
                    "city": "Panorama City",
                    "state": "California",
                    "zip": "91402",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.22473,
                        "lon": -118.44981
                    }
                },
                {
                    "facility": "Site 233",
                    "status": "RECRUITING",
                    "city": "Santa Ana",
                    "state": "California",
                    "zip": "92704",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.74557,
                        "lon": -117.86783
                    }
                },
                {
                    "facility": "Site 210",
                    "status": "WITHDRAWN",
                    "city": "Sarasota",
                    "state": "Florida",
                    "zip": "34240",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.33643,
                        "lon": -82.53065
                    }
                },
                {
                    "facility": "Site 211",
                    "status": "RECRUITING",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78757",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "Site 213",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Edinburg",
                    "state": "Texas",
                    "zip": "78539",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 26.30174,
                        "lon": -98.16334
                    }
                },
                {
                    "facility": "Site 305",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77079",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Site 212",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "226",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98105",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005234",
                    "term": "Fatty Liver"
                },
                {
                    "id": "D000065626",
                    "term": "Non-alcoholic Fatty Liver Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M8375",
                    "name": "Fatty Liver",
                    "asFound": "Steatohepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30540",
                    "name": "Non-alcoholic Fatty Liver Disease",
                    "asFound": "Nonalcoholic Steatohepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5868",
                    "name": "Visceral Steatosis",
                    "asFound": "Steatohepatitis",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003348",
                    "term": "Cortisone"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                },
                {
                    "id": "M6569",
                    "name": "Cortisone",
                    "asFound": "Tremelimumab",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                }
            ]
        }
    },
    "hasResults": false
}